Prednisolone/zoledronic acid

Drug Profile

Prednisolone/zoledronic acid

Alternative Names: VOLT-01

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator Levolta Pharmaceuticals
  • Developer Levolta Pharmaceuticals; Menzies Research Institute Tasmania
  • Class Anti-inflammatories; Bisphosphonates; Calcium regulators; Corticosteroids; Drug conjugates; Glucocorticoids; Imidazoles; Osteoporosis therapies; Pregnadienetriols; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Glucocorticoid receptor agonists; HMG-CoA reductase inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Osteoarthritis

Most Recent Events

  • 28 Dec 2016 Levolta Pharmaceuticals completes a phase III trial in Osteoarthritis in Australia (IV) before December 2016 (Levolta Pharmaceuticals pipeline)
  • 18 Nov 2014 Efficacy & adverse events data from a phase II trial in Osteoarthritis presented at the Annual Meeting of the American College of Rheumatology (ACR-2014)
  • 20 May 2014 Phase-II clinical trials in Osteoarthritis in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top